Identify Peripheral Biomarkers of Symptomatology, Neurocognitive Functions, and Medication Response in ADHD
Status:
Unknown status
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
Attention deficit hyperactivity disorder (ADHD), characterized by inattention, hyperactivity
and impulsivity, is an early onset, highly heritable, clinically heterogeneous, long-term
impairing disorder with tremendous impact on individuals, families, and societies. It affects
5-10% of school-aged children worldwide (7.5% in Taiwan) and 2-4% of adults. Although the
efficacy of medications for ADHD is well demonstrated in clinical trials, substantial numbers
of patients fail to remain on therapy, and there is tremendous variability in tolerability
and treatment acceptance. It is of great interest to identify biomarkers relating to
medication response in ADHD. However, the procedure for obtaining central markers such as PET
scan is invasive and expensive. Previous studies have found that mRNA expression of
neurochemical markers in circulating blood can reflect the neurochemical levels in the brain.
Further studies to identify peripheral biomarkers related to medication response in ADHD are
warranted.